Understanding the risk of recurrent atrial fibrillation after heart procedure

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study involves collecting clinical data from patients with atrial fibrillation who have undergone catheter ablation at Peking University Third Hospital. The aim is to identify risk factors associated with the recurrence of atrial fibrillation and to analyze major clinical events in these patients through outpatient follow-up. By continuously including patients in the study, researchers hope to enhance the management strategies for atrial fibrillation. The study focuses on understanding how different factors influence patient outcomes post-ablation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\) Age \> 18
* 2\) ECG or holter electrocardiogram confirmed atrial fibrillation

Exclusion Criteria:

* 1\) Hematological diseases, autoimmune diseases and malignant tumors
* 2\) Immobility caused by hemiplegia or severe trauma
* 3\) The expected survival time is less than 2 years
* 4\) Poor compliance and high risk of expected loss of follow-up
* 5\) Disorders of consciousness or Alzheimer's disease

Where it's running

• Peking-University-Third-Hospital
  Beijing, China Recruiting

Study contacts

• Study coordinator: Yanguang Li, Doctor
• Email: liyanguangsuper@163.com
• Phone: +8613693327068

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals

  This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.

  Recruiting at 2 sites Hospital Universitari Vall d'Hebron Research Institute · Leuven and 6 other locations · NCT07924371

• Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities

  This study tests how comorbid conditions like sleep apnea and primary aldosteronism relate to left-atrial fibrosis and AF recurrence in patients undergoing ablation.

  Recruiting University Hospital Augsburg · Augsburg, Bavaria · NCT07857044

• Dual Energy ablation with SmartTouch SF catheter in persistent atrial fibrillation

  This study tests a pulsed field and radiofrequency ablation system to treat persistent atrial fibrillation in adults who have not responded well to prior medications.

  Recruiting at 4 sites Biosense Webster, Inc. · Beijing and 3 other locations · NCT07845682

• Identifying AF patients who may need more than standard ablation using Volta AF-Xplorer II

  This trial tests whether AI-identified dispersion areas during AF ablation can predict recurrence after a standard pulmonary vein isolation in patients with persistent AF.

  Recruiting Volta Medical · Avignon and 4 other locations · NCT07807423

• 4D intracardiac echocardiography to guide left atrial appendage occlusion procedures

  A new 4D ICE catheter is being tested alongside standard imaging to see if it can safely guide left atrial appendage occlusion procedures for adults with atrial fibrillation.

  Recruiting The Cleveland Clinic · Cleveland, Ohio · NCT07806890

• Thoracoscopic vs Catheter Ablation as the First Rhythm Control in Atrial Fibrillation with a Large Left Atrium

  This trial tests whether thoracoscopic surgical ablation is better at keeping atrial fibrillation under control than catheter ablation in people with persistent AF and a large left atrium who have not had an ablation before.

  Recruiting Samsung Medical Center · Seoul, Seoul · NCT07783984

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.